JLL Partners poised for 60-plus-pct IRR on Patheon exit

JLL Partners, Patheon NV, Thermo Fisher Scientific, healthcare, private equity, merger, M&A
  • JLL acquired 51 pct stake in Patheon in 2014
  • Most of firm’s equity came from Fund VI
  • Deal values Patheon at $3.8 bln
JLL Partners stands to make 4x to 5x its investment in Patheon NV, according to a source with knowledge of the deal. Thermo Fisher Scientific is expected to close its acquisition of the drug-manufacturing business in the next three to five ...
DON'T MISS OUT! Meet new and diverse managers in private equity, venture capital and real estate at the third Emerging Manager Connect East at New York City's Harvard Club. CLICK HERE FOR DETAILS!

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition


To read a digital copy of our latest magazine

click here

PE News Briefs